The Epoch Times
The Epoch Times
AD
The Epoch Times
Support Us
Companies

Major Drugmaker to Drastically Reduce Insulin Prices in United States

Major Drugmaker to Drastically Reduce Insulin Prices in United States
A high-speed production line of insulin at the factory of Novo Nordisk in Chartres, France, on Feb. 17, 2014. Francois Monier/AFP/Getty Images
Naveen Athrappully
Naveen Athrappully
Reporter
3/15/2023|Updated: 3/15/2023
0:00

Drugmaker Novo Nordisk has announced that it will significantly reduce insulin prices in the United States beginning next year—a relief for Americans struggling with high prices.

Denmark-based Novo Nordisk will lower U.S. prices of several pre-filled insulin pens and vials by up to 75 percent for people living with Type 1 and Type 2 diabetes, the company said in a press release on Mar. 14. The new prices will come into effect on Jan. 1, 2024. The company’s Novolin and Levemir legacy insulin brands will see a price cut of 65 percent from their current list price. The other two legacy insulin brands, NovoLog and NovoLog Mix 70/30, will see prices reduced by 75 percent.
Naveen Athrappully
Naveen Athrappully
Reporter
Naveen Athrappully is a news reporter covering business and world events at The Epoch Times.
Author’s Selected Articles

IRS Reminds Taxpayers to File 2024 Taxes Before End of Oct. 15

Oct 15, 2025
IRS Reminds Taxpayers to File 2024 Taxes Before End of Oct. 15

US Uncovering Financial Networks Behind Domestic Terrorism, Bessent Says

Oct 15, 2025
US Uncovering Financial Networks Behind Domestic Terrorism, Bessent Says

Homeland Security Issues Warning Against Doxxing of ICE Agents

Oct 15, 2025
Homeland Security Issues Warning Against Doxxing of ICE Agents

WHO Warns of Widespread Resistance Against Antibiotics Worldwide

Oct 14, 2025
WHO Warns of Widespread Resistance Against Antibiotics Worldwide
Related Topics
type 2 diabetes
insulin
type 1 diabetes
affordable insulin
Add to My List
Save
The Epoch Times
To ensure we reach the high standards of reliability and neutrality that you expect from us, we are engaging with Ad Fontes Media to analyze our content. If you find an article you think falls short of the standard, please submit the link through this form.
Copyright © 2000 - 2025 The Epoch Times Association Inc. All Rights Reserved.